Keep up-to-date with PrECOG by visiting our news page regularly.
The approval introduces a new maintenance treatment option for patients with HR+/HER2+ advanced breast cancer, following a global academic collaboration that includes PrECOG.
PrECOG, LLC, collaborated with global partners on the first large, randomized phase 3 study to show a clinical benefit for CDK4/6 inhibition in HR+, HER2+ metastatic disease, resulting in a 15-month improvement in progression-free survival.